We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

HospiMedica

Download Mobile App
Recent News AI Critical Care Surgical Techniques Patient Care Medical Imaging Health IT Point of Care Business Focus

Resorbable Pacing Leads Can Significantly Reduce Risk After Cardiac Surgery

By HospiMedica International staff writers
Posted on 04 Nov 2022
Image: After the postoperative monitoring period, the resorbable pacing leads slowly degrade in the body (Photo courtesy of Fraunhofer Society)
Image: After the postoperative monitoring period, the resorbable pacing leads slowly degrade in the body (Photo courtesy of Fraunhofer Society)

Postoperative cardiac arrhythmias are common after cardiac surgery. They are routinely treated with external pacemakers and temporary pacing leads that are prophylactically implanted at the time of surgery. This is inherently associated with several risks: Manually extracting modern stainless steel pacing leads can result in complications as the wires can, in some cases, resist extraction due to tissue in-growth. However, if the leads are cut and left in the body, there is the risk of infection and migration; in the case of the latter, revision surgery may be required. Now, a team of researchers is developing resorbable pacing leads that can significantly reduce risk factors after cardiac surgery.

In the project “Resorbable Molybdenum Temporary Cardiac Electrodes,” or “ReMoTe CarE” for short, researchers from the Fraunhofer Society (Munich, Germany) are investigating a completely new approach: In the future, bioresorbable leads that can be left in the body and then disappear by resorption after a defined period are expected to replace conventional leads. This approach is based on the use of the metal molybdenum (Mo), which offers several advantages, such as the ability to degrade uniformly in the body, biocompatibility, and high mechanical strength and electrical conductivity. For use in bioresorbable pacing leads, it is coated with resorbable biopolymers to electrically insulate the surrounding tissue.

The researchers are testing and optimizing the mechanical, electrical and degradation properties of the materials used. The demonstrators - strands of fine metal wires that are coated with biopolymers - will be tested in preclinical studies. The objective is to avoid the complications associated with non-resorbable pacing leads. This would not only provide great relief to patients but also significantly relieve the burden on both healthcare professionals and the healthcare system.

Related Links:
Fraunhofer Society

Gold Member
12-Channel ECG
CM1200B
Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Blood Pressure Monitor
Cuff Blood Pressure Monitor
Hypodermic Syringe
SurTract™ Safety Syringe

Channels

Patient Care

view channel
Image Credit: Adobe Stock

AI Platform Personalizes Support Between Visits for Cancer Survivors

Cancer survivors often manage persistent side effects after treatment, including fatigue, anxiety, uncertainty, symptoms, stress, and questions between appointments. Clinical teams need ways to maintain... Read more

Medical Imaging

view channel
Image: The tool analyzes 3D time-of-flight MR angiography to measure brain vessel length, radius, volume, branching, tortuosity, and other structural features. (Photo courtesy of University of Rochester Medical Center)

MRI Tool Analysis Identifies Vascular Differences in Cerebral Small Vessel Disease

Cerebral small vessel disease (CSVD) involves changes or damage to the brain’s small blood vessels and is associated with stroke and cognitive impairment. Magnetic resonance imaging (MRI) can show cerebral... Read more

Point of Care

view channel
Image Credit: 123RF

Continuous Glucose Monitoring Identifies Cardiometabolic Risk in Adults Without Diabetes

Dysglycemia—abnormal blood glucose regulation—can fluctuate throughout the day and often escape conventional screening. Clinicians typically rely on fasting plasma glucose and hemoglobin A1c, which offer... Read more

Business

view channel
Image: The proposed acquisition would add NeoCast, an investigational next-generation liquid embolic technology for chronic subdural hematoma (cSDH), to Terumo Neuro’s neurovascular portfolio. (Photo courtesy of Arsenal Medical)

Terumo Neuro Acquisition Advances Liquid Embolic Technology for Chronic Subdural Hematoma

Terumo Neuro (Aliso Viejo, CA, USA) signed an agreement to acquire Arsenal Medical Inc. (Waltham, MA, USA), a privately held, clinical-stage biomaterials company. The proposed acquisition would add NeoCast,... Read more